These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 19734170)

  • 21. Biliary secretion of moxifloxacin in obstructive cholangitis and the non-obstructed biliary tract.
    Schwab D; Grauer M; Hahn EG; Mühldorfer S
    Aliment Pharmacol Ther; 2005 Sep; 22(5):417-22. PubMed ID: 16128679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and milk penetration of moxifloxacin after intramuscular administration to lactating goats.
    Cárceles CM; Villamayor L; Escudero E; Marín P; Fernández-Varón E
    Vet J; 2007 Mar; 173(2):452-5. PubMed ID: 16377219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of 2 moxifloxacin regimens for preoperative prophylaxis: prospective randomized triple-masked trial. Part 1: aqueous concentration of moxifloxacin.
    Vasavada AR; Gajjar D; Raj SM; Vasavada V; Vasavada V
    J Cataract Refract Surg; 2008 Aug; 34(8):1379-82. PubMed ID: 18655991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy.
    Murillo O; Pachón ME; Euba G; Verdaguer R; Tubau F; Cabellos C; Cabo J; Gudiol F; Ariza J
    J Infect; 2009 Mar; 58(3):220-6. PubMed ID: 19217166
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liver tissue concentrations of levofloxacin after single intravenous administration of 500 mg for antibiotic prophylaxis in liver surgery.
    Weinrich M; Scheingraber S; Stremovskaia T; Schilling MK; Kees F; Pistorius GA
    Int J Antimicrob Agents; 2006 Sep; 28(3):221-5. PubMed ID: 16904875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics after intravenous, intramuscular and subcutaneous administration of moxifloxacin in sheep.
    Cárceles CM; Escudero E; Fernández-Varón E; Marín P
    Vet J; 2009 Jun; 180(3):343-7. PubMed ID: 18406644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis.
    Starakis I; Gogos CA; Bassaris H
    Int J Antimicrob Agents; 2004 Feb; 23(2):129-37. PubMed ID: 15013037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and milk penetration of moxifloxacin after intravenous and subcutaneous administration to lactating goats.
    Fernández-Varón E; Villamayor L; Escudero E; Espuny A; Cárceles CM
    Vet J; 2006 Sep; 172(2):302-7. PubMed ID: 15908243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diffusion of oral and intravenous 400 mg once-daily moxifloxacin into lung tissue at pharmacokinetic steady-state.
    Breilh D; Jougon J; Djabarouti S; Gordien JB; Xuereb F; Velly JF; Arvis P; Landreau V; Saux MC
    J Chemother; 2003 Dec; 15(6):558-62. PubMed ID: 14998080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients.
    Kees MG; Schaeftlein A; Haeberle HA; Kees F; Kloft C; Heininger A
    J Antimicrob Chemother; 2013 Jun; 68(6):1331-7. PubMed ID: 23463212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate.
    Lipsky BA; Giordano P; Choudhri S; Song J
    J Antimicrob Chemother; 2007 Aug; 60(2):370-6. PubMed ID: 17553812
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conjunctival tissue pharmacokinetic properties of topical azithromycin 1% and moxifloxacin 0.5% ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteers.
    Torkildsen G; O'Brien TP
    Clin Ther; 2008 Nov; 30(11):2005-14. PubMed ID: 19108788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ophthalmic infections and their anti-infective challenges.
    Alfonso E; Crider J
    Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S1-6. PubMed ID: 16257307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The role of moxifloxacin in the prophylaxis of post-surgical endophthalmitis].
    Villalobos PA; Valle DD
    Arch Soc Esp Oftalmol; 2010 Oct; 85(10):323-4. PubMed ID: 21168055
    [No Abstract]   [Full Text] [Related]  

  • 35. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
    Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
    Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diffusion of ertapenem into bone and synovial tissues.
    Boselli E; Breilh D; Djabarouti S; Bel JC; Saux MC; Allaouchiche B
    J Antimicrob Chemother; 2007 Oct; 60(4):893-6. PubMed ID: 17704514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neither moxifloxacin nor cefuroxime produces significant attenuation of inflammatory mediator release in patients exposed to cardiopulmonary bypass: a randomized controlled trial.
    Wiesner G; Braun SL; Gruber M; Gertler R; Lange R; Tassani P; Martin K
    J Antimicrob Chemother; 2012 Jan; 67(1):230-3. PubMed ID: 21972268
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections.
    Kontou P; Manika K; Chatzika K; Papaioannou M; Sionidou M; Pitsiou G; Kioumis I
    Int J Antimicrob Agents; 2013 Sep; 42(3):262-7. PubMed ID: 23830621
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibiotic therapy in biliary tract infections: clinical experiences with mezlocillin.
    Cristiano P; Iovene MR; Cioffi R; Salerno RA; Sicolo A; Cristinzio G; Paradisi F
    Chemioterapia; 1984 Jun; 3(3):178-82. PubMed ID: 6529774
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose.
    Rodvold KA; Gotfried MH; Cwik M; Korth-Bradley JM; Dukart G; Ellis-Grosse EJ
    J Antimicrob Chemother; 2006 Dec; 58(6):1221-9. PubMed ID: 17012300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.